Form 4 for KURA Kura Oncology, Inc.
Accepted 2026-08-24 17:30:03 ET · period of report 2026-08-21 · accession 0001193125-26-363810 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| T | 2026-08-24 17:30 | 2026-08-21 | KURA | Powl Brian T. | Chief Commercial Off | S - Sale | $11.89 | -4,345 | 169.3K | -3% | -$51.7K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-08-21 | S | D | 4,345 | $11.89 | 169,269 | D | — | — | (F1) The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 18, 2025. (F2) This transaction was executed in multiple trades at prices ranging from $11.78 to $12.00. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |